Consensus Pyxis Oncology, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
4.17 ^USD	-0.95%		-7.54%	+131.67%

May. 14	Earnings Flash (PYXS) PYXIS ONCOLOGY Posts Q1 Revenue $16.1M	MT
May. 14	Pyxis Oncology, Inc. Appoints Stephen Worsley as its Senior Vice President	CI

6cc34515548f6.TIfKOJ67p-VU1kP86nrcbb7WwxZE3KhKDmNOXoBWl0Q.K7GzevjJ9KJkghWNgQu4VOfg838NuOYDPSYeDdkvxAwC7Lxv0f72ixbmJA~f0c7a501aca97e3a2399f5f0a5422bb0

H.C. Wainwright Adjusts Price Target on Pyxis Oncology to $7 From $4, Maintains Buy Rating	Mar. 22	MT
BTIG Initiates Pyxis Oncology With Buy Rating, $8 Price Target	Feb. 09	MT
Leerink Partners Initiates Coverage on Pyxis Oncology with Outperform Rating, $12 Price Target	Jan. 23	MT
HC Wainwright Starts Pyxis Oncology With Buy Rating, $4 Price Target	Nov. 30	MT
RBC Initiates Pyxis Oncology at Outperform With Speculative Risk, Sets Price Target at $7, Sees 'Favorable' Risk/Reward	23-09-05	MT
Credit Suisse Starts Pyxis Oncology at Outperform with $19 PT on Potential of Antibody-Drug Conjugate for Cancer	21-11-02	MT
Jefferies Starts Pyxis Oncology at Buy with $25 Price Target	21-11-02	MT
BofA Securities Starts Pyxis Oncology at Neutral With $16 Price Target	21-11-02	MT

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.17 USD

Average target price

8 USD

Spread / Average Target

+91.85%

High Price Target

10 USD

Spread / Highest target

+139.81%

Low Price Target

7 USD

Spread / Lowest Target

+67.87%